



Ref: Syn/CS/SE/Reg 30/2024-25/Mar/05

**Syngene International Limited**  
Biocon SEZ, Biocon Park, Plot No. 2 &  
3, Bommasandra Industrial Area,  
IV Phase, Jigani Link Road,  
Bengaluru 560 099, Karnataka, India  
T +91 80 6891 8000  
CIN: L85110KA1993PLC014937  
[www.syngeneintl.com](http://www.syngeneintl.com)

March 10, 2025

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
<b>Scrip Code: 539268</b>	<b>Scrip Symbol: SYNGENE</b>

Dear Sir/Madam,

**Sub: Investment in Syngene USA Inc, a wholly owned subsidiary of the Company.**

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we wish to inform you that the Company would be making an additional investment of upto USD 56 Millions in equity share capital of Syngene USA Inc (SUSA), a wholly owned subsidiary of the Company, in one or more tranches.

The details required in terms of Regulation 30, read with Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed as "Annexure – I".

The above-mentioned information will also be available on the website of the Company [www.syngeneintl.com](http://www.syngeneintl.com).

kindly take this information on record.

Yours faithfully,  
For **SYNGENE INTERNATIONAL LIMITED**

\_\_\_\_\_  
**Priyadarshini Mahapatra**  
**Head Legal, Company Secretary & Compliance Officer**  
Encl. : a/a

**Details as per the SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024**

Sr. no.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc	<p>Syngene USA Inc (“SUSA”) is a wholly owned subsidiary of the Company incorporated in Delaware, USA in August 2017. SUSA serves as a strategic arm to expand the Company’s presence in the US market.</p> <p>The turnover for FY 2023-24 of SUSA was USD 73,32,492</p>
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	<p>The transaction is between holding company and a wholly owned subsidiary. Accordingly, Audit Committee/Shareholders’ approval is not applicable under Regulation 23.</p> <p>None of the promoter/promoter group/group companies have any interest in the entity.</p>
3	Industry to which the entity being acquired belongs;	Marketing Services [for Contract Research, Development & Manufacturing Organization (CRDMO)]
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The investment will be utilised to finance the cost of acquisition of biologics facility from Emergent Manufacturing Operations Baltimore, LLC., and for meeting the general corporate, and day-to-day operating requirements.
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
6	Indicative time period for completion of the acquisition	The investment is expected to be completed on or before March 31, 2026 or such other date mutually agreed between the parties.
7	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
8	Cost of acquisition or the price at which the shares are acquired	Cost of acquisition: Upto USD 5,60,00,000 (USD Fifty-Six Million Only) in one or more tranches
9	Percentage of shareholding / control acquired and /or number of shares acquired	There will be no change in shareholding of the Company in SUSA. SUSA will continue to

Sr. no.	Particulars	Details								
		remain a wholly owned subsidiary of the Company.								
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3-year turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p data-bbox="850 327 1240 352">Brief background: Refer (1) above.</p> <p data-bbox="850 390 1292 415">Date of Incorporation: August 24, 2017</p> <p data-bbox="850 453 1208 478">History of last 3 years turnover:</p> <table border="1" data-bbox="850 516 1378 659"> <thead> <tr> <th data-bbox="859 527 1117 552">Financial Year</th> <th data-bbox="1117 527 1370 552">Turnover (in USD)</th> </tr> </thead> <tbody> <tr> <td data-bbox="859 558 1117 583">2023-24</td> <td data-bbox="1117 558 1370 583">73,32,492</td> </tr> <tr> <td data-bbox="859 590 1117 615">2022-23</td> <td data-bbox="1117 590 1370 615">55,17,593</td> </tr> <tr> <td data-bbox="859 621 1117 646">2021-22</td> <td data-bbox="1117 621 1370 646">37,52,450</td> </tr> </tbody> </table> <p data-bbox="850 695 1357 720">Country in which SUSA has its presence: USA</p>	Financial Year	Turnover (in USD)	2023-24	73,32,492	2022-23	55,17,593	2021-22	37,52,450
Financial Year	Turnover (in USD)									
2023-24	73,32,492									
2022-23	55,17,593									
2021-22	37,52,450									